Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LUMO Lumos Pharma	$4.34	$4.34	$1.37 ▼ $4.58	$37.54M	0.74	96,055 shs	N/A
MRKR MARKER THERAPEUTICS	$1.58 +0.4%	$1.36	$0.95 ▼ $5.99	$18.10M	1.43	80,181 shs	33,364 shs
PCSA Heatwurx	$0.19 +2.4%	$0.26	$0.15 ▼ $3.10	$2.32M	1.3	4.94 million shs	2.85 million shs
STSA Satsuma Pharmaceuticals	$1.10	$1.08	$0.59 ▼ $8.08	$36.47M	0.1	701,788 shs	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LUMO Lumos Pharma	0.00%	0.00%	0.00%	0.00%	+97.27%
MRKR MARKER THERAPEUTICS	0.00%	+7.95%	+4.37%	+55.89%	-69.63%
PCSA Heatwurx	0.00%	-1.63%	-37.26%	-43.24%	-89.34%
STSA Satsuma Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LUMO Lumos Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRKR MARKER THERAPEUTICS	3.211 of 5 stars	3.8	3.0	0.0	3.9	0.0	0.8	0.6
PCSA Heatwurx	3.668 of 5 stars	3.5	5.0	0.0	0.0	2.5	1.7	1.3
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LUMO Lumos Pharma	3.00	Buy	$8.63	98.73% Upside
MRKR MARKER THERAPEUTICS	3.50	Strong Buy	$13.17	735.45% Upside
PCSA Heatwurx	3.00	Buy	$2.00	936.27% Upside
STSA Satsuma Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LUMO, PCSA, STSA, and MRKR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/30/2025	PCSA Heatwurx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $2.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LUMO Lumos Pharma	$2.21M	17.02	N/A	N/A	$3.45 per share	1.26
MRKR MARKER THERAPEUTICS	$6.59M	2.70	N/A	N/A	$1.73 per share	0.91
PCSA Heatwurx	N/A	N/A	N/A	N/A	$0.46 per share	N/A
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LUMO Lumos Pharma	-$34.03M	-$4.29	N/A	N/A	N/A	-1,583.49%	-233.03%	-129.88%	N/A
MRKR MARKER THERAPEUTICS	-$10.73M	-$1.33	0.00	N/A	N/A	-224.46%	-101.87%	-83.02%	8/13/2025 (Estimated)
PCSA Heatwurx	-$11.85M	-$3.08	0.00	N/A	N/A	N/A	-319.56%	-232.40%	8/12/2025 (Estimated)
STSA Satsuma Pharmaceuticals	-$70.06M	-$2.01	N/A	N/A	N/A	N/A	-115.24%	-102.26%	N/A

Latest LUMO, PCSA, STSA, and MRKR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	PCSA Heatwurx	-$0.77	-$0.30	+$0.47	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LUMO Lumos Pharma	N/A	N/A	N/A	N/A	N/A
MRKR MARKER THERAPEUTICS	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	N/A
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LUMO Lumos Pharma	N/A	2.66	2.66
MRKR MARKER THERAPEUTICS	N/A	6.79	6.79
PCSA Heatwurx	N/A	2.93	2.93
STSA Satsuma Pharmaceuticals	N/A	7.44	7.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LUMO Lumos Pharma	33.99%
MRKR MARKER THERAPEUTICS	22.39%
PCSA Heatwurx	91.93%
STSA Satsuma Pharmaceuticals	93.26%

Insider Ownership

Company	Insider Ownership
LUMO Lumos Pharma	25.40%
MRKR MARKER THERAPEUTICS	14.50%
PCSA Heatwurx	9.60%
STSA Satsuma Pharmaceuticals	31.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LUMO Lumos Pharma	30	8.65 million	6.45 million	Not Optionable
MRKR MARKER THERAPEUTICS	60	11.31 million	9.67 million	Not Optionable
PCSA Heatwurx	20	11.88 million	10.74 million	Not Optionable
STSA Satsuma Pharmaceuticals	21	33.15 million	22.81 million	Not Optionable

LUMO, PCSA, STSA, and MRKR Headlines

Recent News About These Companies

Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting

June 19, 2025 | prnewswire.com

Durham-based Satsuma wins FDA approval for migraine treatment

May 21, 2025 | ncbiotech.orgN

Non-Postoperative Acute Pain Market Poised for Significant Expansion by 2034, Amid FDA Approvals and Innovative Therapeutic Pipeline | DelveInsight

May 16, 2025 | theglobeandmail.com

FDA approves Atzumi for acute migraine treatment in adults

May 6, 2025 | healio.comH

FDA Okays Dihydroergotamine Nasal Spray for Acute Migraine

May 5, 2025 | medscape.comM

Nasal Powder for Acute Migraine Gets FDA Nod

May 2, 2025 | msn.com

FDA clears Satsuma’s Atzumi for migraine

May 2, 2025 | bioworld.comB

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi

May 1, 2025 | contractpharma.comC

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

April 30, 2025 | prnewswire.com

Satsuma Pharmaceuticals Inc (STSA)

April 10, 2025 | uk.investing.com

Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura

November 26, 2024 | prnewswire.com

SNBL’s Subsidiary Resubmits Migraine Drug Application

October 31, 2024 | markets.businessinsider.com

Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura

October 30, 2024 | prnewswire.com

Aprea Therapeutics (NASDAQ:APRE) Stock Quotes, Forecast and News Summary

October 10, 2024 | benzinga.com

Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs

October 8, 2024 | prnewswire.com

Satsuma, AL Weather Conditions

August 21, 2024 | wunderground.comW

Satsuma pulped as acute migraine drug flunks phase 3 trial

August 9, 2024 | pharmaphorum.comP

Satsuma, FL Weather Conditions

July 29, 2024 | wunderground.comW

Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting

June 13, 2024 | prnewswire.com

With manufacturing-related rejection, FDA turns its nose up at Satsuma's migraine nasal spray

January 18, 2024 | fiercepharma.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUMO, PCSA, STSA, and MRKR Company Descriptions

Lumos Pharma NASDAQ:LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

MARKER THERAPEUTICS NASDAQ:MRKR

$1.58 +0.01 (+0.38%)

As of 07/3/2025 03:16 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Heatwurx NASDAQ:PCSA

$0.19 +0.00 (+2.39%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$0.19 0.00 (0.00%)

As of 07/3/2025 04:55 PM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Satsuma Pharmaceuticals NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time